• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

• 药品评价-循证医学研究 • 上一篇    下一篇

参附注射液在心脏手术中心肌保护作用的荟萃分析

马敬,郭建华,叶玮   

  1. 同济大学附属东方医院南院 外科监护室,同济大学附属东方医院南院 外科监护室,同济大学附属东方医院 外科监护室
  • 收稿日期:2015-03-28 修回日期:2015-06-02 出版日期:2015-06-25 发布日期:2015-06-25

Shenfu Injection myocardial protection during cardiac surgery in the meta-analysis

马敬,郭建华 and 叶玮   

  1. Shanghai East Hospital,,
  • Received:2015-03-28 Revised:2015-06-02 Online:2015-06-25 Published:2015-06-25

摘要: 目的 采用Meta分析的方法,评价参附注射液在心脏手术中心肌保护作用之功效。 方法 制定原始文献的纳入标准及检索策略,检索维普中文科技期刊全文数据库(VIP)和万方医学数据库,提取有关心脏手术中应用参附注射液病例的随机对照研究( RCT)文献,评价纳入研究的文献质量,并提取有效数据后采用RevMan5.0 软件进行meta分析。 结果 纳入研究的18篇文献,共计900例符合纳入标准。Meta分析结果显示:参附组与对照组有关心脏自动复跳率的OR合并值3.90(95%CI为2.23~6.80),P<0.00001,差异有统计学意义;术后1~2小时内血肌钙蛋白(cTnI)检测值的加权均数差(MD)值-0.18(95%CI为-0.24~-0.12),P<0.00001,,差异有统计学意义;术后拔除气管插管时间的加权均数差(MD)值-3.39(95%CI为-4.18~-2.59),P<0.00001,差异有统计学意义。结论 参附注射液在心脏手术中心肌保护应用效果显著。但仍需要高质量的临床证据进一步验证,尤其是参附注射液不同用药途径以及不同用药量之间的比较,需大样本研究资料验证。

Abstract: Meta-analysis of Shenfu Injection in the Protective Effect of Muscle Cardiac Surgery Center (Shanghai East Hospital,Shanghai 200123,China) [Abstract]Objective:To evaluate the use of shenfu injection, in the open heart surgery for the circulation protection in cardiopulmonary bypass operation. Methods: Set the inclusive criteria and search strategy,research the VIP database and Wanfang database,draw the RCT papers regarding the open heart surgeries, the quality of the papers was analyzed. Meta-analyze the data with RevMan 5.0 software. Results:18 papers were analyzed, 900 cases fit the inclusive criteria. Meta analysis reveals the combined value of automatic heart resuscitating rate in the Shenfu group and the control group is 3.90 (95% CI:2.23~6.80), P<0.00001, with statistical significance. The MD of cTNT level 1~2 hour after the operation is -0.18(95%CI:-0.24~-0.12),P<0.00001,with statistical significance. The MD of extubation time is -3.39(95%CI:-4.18~-2.59),P<0.00001,with statistical significance.Conclusion:Shenfu injection is of significant value in the cardiopulmonary bypass operations, however huge amount of high quality clinical evidences are still requested to prove the outcome of the medicine. Especially the comparison of outcome by the various administration routes and diffent dosages needs to be classified by the study on large samples.